Trial reportFertility and sterility2010
Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914.
Trial report in Fertility and sterility, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 98 citations in OpenAlex.
- Ulipristal acetate for use in medical management of early pregnancy loss: a pilot feasibility study.BMC pregnancy and childbirth · 2026Trial
- Trial
- Results from pooled Phase III studies of ulipristal acetate for emergency contraception.Contraception · 2012Trial
- Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.Endocrine reviews · 2020Review
- 90 YEARS OF PROGESTERONE: Selective progesterone receptor modulators in gynaecological therapies.Journal of molecular endocrinology · 2020Review
- A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma.BioMed research international · 2018Review
- Clinical Pharmacology of Hormonal Emergency Contraceptive Pills.International journal of reproductive medicine · 2018Review
- Emergency contraception. Widely available and effective but disappointing as a public health intervention: a review.Human reproduction (Oxford, England) · 2015Review
- Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.Clinical pharmacokinetics · 2015Review
- Mechanism of Action of Ulipristal Acetate for Emergency Contraception: A Systematic Review.Frontiers in pharmacology · 2015Review
- Nuclear receptors and their selective pharmacologic modulators.Pharmacological reviews · 2013Review
- Emerging options for emergency contraception.Clinical medicine insights. Reproductive health · 2013Review
- The role of progesterone signaling in the pathogenesis of uterine leiomyoma.Molecular and cellular endocrinology · 2012Review
- Ulipristal acetate, a progesterone receptor modulator for emergency contraception.Journal of pharmacology & pharmacotherapeutics · 2012Article
- Emergency contraception: an updated review.Translational medicine @ UniSa · 2011Article
- Review
- Immunopharmacology of ulipristal as an emergency contraceptive.International journal of women's health · 2011Article
- Emergency contraception: potential role of ulipristal acetate.International journal of women's health · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo test potential contraceptive mechanisms of the selective P receptor modulator CDB-2914 in the early luteal phase.
designProspective randomized clinical trial.
settingClinical research center. PATIENT(S): Fifty-six women with regular cycles. INTERVENTION(S): Women received a single dose of CDB-2914 (10, 50, or 100 mg) or placebo given after ovulation and within 2 days of the LH surge. Four to 6 days later, a transvaginal ultrasound scan measured endometrial thickness, and an endometrial biopsy specimen was obtained. MAIN OUTCOME MEASURE(S): The endometrium was evaluated by thickness and by immunohistochemical analysis for P-dependent markers; safety laboratory tests were performed, and E(2) and P levels were obtained. RESULT(S): CDB-2914 caused a significant dose-dependent decrease in endometrial thickness, an increase in glandular P receptors, and a decrease in peripheral node addressins. Estradiol and P levels and menstrual cycle timing were not altered. No adverse effects were observed. CONCLUSION(S): The alteration in endometrial thickness and P-dependent markers of implantation in the absence of changes in hormone levels and cycle length suggests that CDB-2914 may have contraceptive properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.